Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Norwegian Cruise Line Holdings Ltd — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Norwegian Cruise Line Holdings Ltd trades at $15.57 (market cap $7.11B). The key difference: Norwegian Cruise Line Holdings Ltd is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| IOVA | NCLH | |
|---|---|---|
Market Cap | $6.04B | $7.11B |
Volume | 14,805,993 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $14.82 | $25.02 |
52-Week Low | $1.81 | $14.12 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $5.97B | $21.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Norwegian Cruise Line Holdings (NCLH) trades at $15.49, up 2.92% with bullish technical signals and strong earnings beats. The company shows improving fundamentals with $9.83B revenue in 2025 and net income of $423M, while maintaining attractive valuation metrics including a 9.39 P/E ratio. Recent news highlights management's expectation for Q3 2026 results to exceed guidance, driven by better-than-expected revenue performance.
NCLH presents a compelling investment case with analyst consensus pointing to 35% upside to the $20.86 price target. However, investors face risks from persistent yield pressure, high debt levels ($11.78B long-term debt), and competitive Caribbean pricing. The stock's outlook remains positive given consecutive earnings beats and management's pricing strategies to stabilize performance through 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
